Coherus Biosciences | CHRS - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 538M 2026-03
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Akebia Therapeutics USD 63.08M 8.26M 2025-12
ALKERMES USD 1.75B 1.43B 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amarin USD 51.48M 113K 2025-12
Amgen USD 4.78B 1.12B 2026-03
Baxter International USD 6.04B 2.85B 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Fujifilm JPY 767.39B 27.7B 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Merck USD 18.17B 8.01B 2026-03
Myriad Genetics USD 212.8M 16.2M 2025-12
Pacira USD 172.75M 20.93M 2026-03
Perrigo USD 1.03B 75.3M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 246.3M 38.78M 2025-12
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03
Xencor USD 81.86M 13.35M 2025-12
Zoetis USD 1.55B 3.85B 2025-12